Patrick Nelson, DPM
Foot & Ankle Surgery · Omaha, NENPI 1902193618
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,562 of the $27,697 with a category attached, or 74.2%. Stryker accounts for 87.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $6,841 and has fallen 54.4% since, to $3,122 in 2025.
Across 500 payments — averaging $55.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$24K
- Smith+Nephew$2K
- Abbott$173
- Amgen$164
- Osiris Therapeutics Inc.$140
- Kerecis Limited$88
- plus $661 from 16 others
What the payments were for
- Travel & lodging$7,13526%
- Food & beverage$20,56274%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 348 | $24,236 |
| Smith+Nephew | 100 | $2,234 |
| Abbott | 2 | $173 |
| Amgen | 12 | $164 |
| Osiris Therapeutics Inc. | 4 | $140 |
| Kerecis Limited | 5 | $88 |
| Organogenesis Inc. | 4 | $74 |
| Innovation Technologies Inc | 3 | $73 |
| Integra Lifesciences Corporation | 2 | $73 |
| Orpyx Medical Technologies US Inc. | 1 | $53 |
| Treace Medical Concepts, Inc. | 2 | $53 |
| GRT US Holding, Inc. | 2 | $45 |
| Averitas Pharma Inc. | 2 | $44 |
| Misonix Inc | 2 | $43 |
| Nevro Corp. | 2 | $40 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| BD | 1 | $32 |
| Orthofix Medical, Inc. | 2 | $28 |
| Conetic Solutions, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Heron Therapeutics, Inc. | 1 | $15 |
| Zimmer Biomet | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORTHOLOC 2 LAPIFUSE$2,509
- PROstep$2,344
- INBONE$1,855
- AUGMENT INJECTABLE$1,851
- INFINITY$1,566
- ORTHOLOC 3DI$1,201
- Viaflow$1,023
- INVISION$871
- PROPHECY$871
- VARIAX$822
- NA$752
- FIXOS$614
- Stravix$554
- TRAUMA$554
- GRAFIX PL$487
- Grafix$437
- OMEGA$337
- ORTHOLOC 3DI CROSSCHECK$324
- ALLOGRAFT$323
- Actishield$319
How this compares
$27,697 in reported general payments places this provider in the 80th percentile of 43 foot & ankle surgery providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 18 | $504 |
| Gabapentin | 20 | $286 |
| Prednisone | 16 | $36 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Omaha
- Bradley CoppleOmaha$83K
- Robert GreenhagenOmaha$29K
- Jonathan RouseOmaha$20K
- Scott NelsonOmaha$16K
- Jordan SikesOmaha$15K
- Shannon LensingOmaha$11K
- Jorge AmaroOmaha$10K
- Kevin GrosshansOmaha$8K
- Kent DinucciOmaha$4K
- Reanen MichaelOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.